

MEDICINAL CHEMISTRY

THIRD EDITION

PART II

EDITED BY

ALFRED BURGER

PROFESSOR OF CHEMISTRY, UNIVERSITY OF VIRGINIA, CHARLOTTESVILLE, VIRGINIA

WILEY-INTERSCIENCE

a Division of John Wiley & Sons

New York · London · Sydney · Toronto

Notice Concerning Trademark or Patent Rights. The listing or discussion in this book of any drug in respect to which patent or trademark rights may exist shall not be deemed, and is not intended as, a grant of, or authority to exercise, or an infringement of, any right or privilege protected by such patent or trademark.

Copyright © 1951, 1960 by Interscience Publishers, Inc.

Copyright © 1970 by John Wiley & Sons, Inc.

All rights reserved. No part of this book may be reproduced by any means, nor transmitted, nor translated into a machine language without the written permission of the publisher.

10 9 8 7 6 5 4 3 2 1

Library of Congress Catalogue Card Number: 69-16124

SBN 471 12346 3

Printed in the United States of America

MEDICINAL CHEMISTRY

THIRD EDITION

Part II

AUTHORS

JAMES H. ACKERMAN
GEORGE W. ANDERSON
FREDERICK L. BACH
B. R. BAKER
JOSEPH W. BAKER
BARRY M. BLOOM
EUGENE D. BRAND
ALFRED BURGER
ARTHUR CAMMARATA
GEORGE CAMOUGIS
OLIVER CARRIER, JR.
A. F. CASY
CHESTER J. CAVALLITO
RALPH G. CHILD
SCOTT J. CHILDRESS
HARRY C. CLEMSON
PAUL W. COLLINS
WILLIAM T. COMER
R. E. COUNSELL
WILLIAM E. COYNE
CHARLES S. DAVIS
R. DEGHENGI
JAIME N. DELGADO
STEPHEN DIVALD
GEORGE O. DOAK
E. C. DOBBS
SIDNEY DOERNBERG
HARRY W. DOUGHERTY
EDWARD F. ELSLAGER
EDWARD L. ENGELHARDT
WILLIAM O. FOYE
LEON D. FREEDMAN
JAMES E. GEARIN
ALLEN W. GOMOLL
D. R. H. GOURLEY
JACK PETER GREEN
FREDERICK A. GRUNWALD
ROBERT P. HALLIDAY
ELIZABETH M. HARDY
SHARON S. HILLERY
JOHN R. E. HOOVER
MAX HUBACHER
EUGENE I. ISAACSON

ARTHUR E. JACOBSON
THOMAS P. JOHNSTON
EUGENE C. JORGENSON
MADELEINE M. JOULLIÉ
C. KAISER
PAUL D. KLIMSTRA
CALVIN M. KUNIN
ARTHUR LEWIS
A. J. MANSON
ALFRED N. MARTIN
HENRY G. MAUTNER
E. L. MAY
ROBERT E. MCMAHON
JOHN A. MONTGOMERY
T. S. OSDENE
GENET L. PARKS
A. R. PATEL
D. PERLMAN
ROGER M. PINDER
PETER I. POLLAK
WILLIAM P. PURCELL
LEONARD M. RICE
OSCAR R. RODIG
D. P. ROMAN
LEWIS J. SARGENT
B. V. RAMA SASTRY
S. N. SAWHNEY
IGNATIUS SCHUMACHER
Y. FULMER SHEALY
ROBERT G. SHEPHERD
JUDITH A. SINGER
R. JOHN STEDMAN
CLEMENT A. STONE
K. SUNDARAM
BERTIL H. TAKMAN
ANDREW S. TOMKUFCEK
JOHN G. TOPLISS
D. J. TRIGGLE
EUGENE D. WEINBERG
THOMAS C. WESTFALL
DONALD T. WITIAK
WILLIAM L. YOST
CHARLES L. ZIRKLE

List of Contributors

Dr. James Howard Ackerman *Senior Research Chemist—Group Leader*
Sterling-Winthrop Research Institute
Rensselaer, New York

Dr. George W. Anderson *Research Fellow*
Lederle Laboratories, American Cyanamid Co.
Pearl River, New York

Dr. Frederick L. Bach *Research Chemist*
Lederle Laboratories, American Cyanamid Co.
Pearl River, New York

Dr. B. R. Baker *Professor of Chemistry*
Department of Chemistry
University of California at Santa Barbara
Santa Barbara, California

Dr. Joseph W. Baker *Research Group Leader*
—*Organic Chemicals Division*
Monsanto Company
St. Louis, Missouri

Dr. Barry M. Bloom *Director, Medicinal Products*
Research and Development Division
Chas. Pfizer and Company, Inc.
Groton, Connecticut

Dr. Eugene D. Brand *Associate Professor of Pharmacology*
University of Virginia School of Medicine
Charlottesville, Virginia

Dr. Alfred Burger *Professor of Chemistry*
University of Virginia
Charlottesville, Virginia

Dr. Arthur Cammarata *Associate Professor of Pharmaceutical Chemistry*
School of Pharmacy
Temple University
Philadelphia, Pennsylvania

Dr. George Camougis *President and Research Director*
New England Research and Development Laboratories
Worcester, Massachusetts;
Professor Affiliate of Physiology
Clark University
Worcester, Massachusetts

Dr. Oliver Carrier, Jr. *Associate Professor of Pharmacology*
The University of Texas Medical School at
San Antonio
San Antonio, Texas

Dr. Alan F. Casy *Faculty of Pharmacy*
University of Alberta
Edmonton, Alberta, Canada

Dr. Chester J. Cavallito *Professor of Medicinal Chemistry*
School of Pharmacy
University of North Carolina
Chapel Hill, North Carolina

Dr. Ralph G. Child *Research Chemist*
Lederle Laboratories, American Cyanamid Co.
Pearl River, New York

Dr. Scott J. Childress *Assistant to Vice President—Research and Development*
Wyeth Laboratories
Radnor, Pennsylvania

Dr. Harry C. Clemson *Assistant Professor of Medicinal Chemistry*
College of Pharmacy
Northeastern University
Boston, Massachusetts

Dr. Paul W. Collins *Senior Research Chemist*
G. D. Searle and Company
Chicago, Illinois

Dr. William T. Comer *Section Leader, Chemical Research*
Mead Johnson Research Center
Evansville, Indiana

Dr. Raymond E. Counsell *Associate Professor of Medicinal Chemistry*
College of Pharmacy and Department of Internal Medicine
University of Michigan
Ann Arbor, Michigan

Dr. William E. Coyne
G. D. Searle & Co.
P.O. Box 5110
Chicago, Illinois

Present Address: Biochemical Research
Laboratories
3 M Company
St. Paul, Minnesota

Dr. Charles S. Davis *School of Medicine*
Upstate Medical Center, State University of
New York
Syracuse, New York

Dr. R. Deghenghi *Director of Research*
Ayerst Research Laboratories
Montreal, Canada

Dr. Jaime N. Delgado *Associate Professor of*
Pharmaceutical Chemistry
College of Pharmacy
The University of Texas at Austin
Austin, Texas

Dr. Stephen Divald *Research Associate,*
Department of Chemistry
University of Pennsylvania
Philadelphia, Pennsylvania

Dr. George O. Doak *Professor of Chemistry*
North Carolina State University
Raleigh, North Carolina

Dr. Edward C. Dobbs *Professor of Pharma-*
cology and Nutritional Therapeutics
School of Dentistry
University of Maryland
Baltimore, Maryland

Sidney Doernberg *Chief Chemist*
Ex-Lax, Inc.
Brooklyn, New York

Dr. Harry William Dougherty *Senior*
Biochemist
Department of Biochemistry
Merck Institute
Rahway, New Jersey

Dr. Edward Faith Elslager *Group Director,*
Organic Chemistry
Research Division
Parke, Davis and Company
Ann Arbor, Michigan

Dr. Edward L. Engelhardt *Assistant*
Director, Medicinal Chemistry Department
Merck Sharp and Dohme Research Laboratories
West Point, Pennsylvania

Dr. William O. Foye *Professor of Chemistry*
Massachusetts College of Pharmacy
Boston, Massachusetts

Dr. Leon D. Freedman *Professor of Chemistry*
North Carolina State University
Raleigh, North Carolina

Dr. James Edward Gearien *Professor of*
Chemistry and Head of the Department
College of Pharmacy
University of Illinois at the Medical Center
Chicago, Illinois

Dr. Allen W. Gomoll *Group Leader,*
Department of Pharmacology
Mead Johnson Research Center
Evansville, Indiana

Dr. D. R. H. Gourley *Professor of*
Pharmacology
University of Virginia School of Medicine
Charlottesville, Virginia

Dr. Jack Peter Green *Professor and Chairman,*
Department of Pharmacology
Mount Sinai School of Medicine
New York, New York

Dr. Frederick A. Grunwald *Administrator,*
Scientific and Technical Affairs
Physical Sciences Department
Mead Johnson Research Center
Evansville, Indiana

Dr. Robert P. Halliday *Chief, Pharmacology*
Section
The Norwich Pharmacal Company
Norwich, New York

Dr. Elizabeth M. Hardy *Literature Scientist*
Lederle Laboratories, American Cyanamid Co.
Pearl River, New York

Sharon S. Hillery
Research Chemist
Hoffmann-La Roche, Inc.
Nutley, New Jersey

Dr. John R. E. Hoover *Associate Director,*
Chemistry
Research Microbiology
Smith Kline and French Laboratories
Philadelphia, Pennsylvania

Dr. Max Heinrich Hubacher *Senior Research*
Chemist
Ex-Lax, Inc.
Brooklyn, New York

Dr. Eugene I. Isaacson *Associate Professor of*
Pharmaceutical Chemistry
College of Pharmacy
Idaho State University
Pocatello, Idaho

Dr. Arthur E. Jacobson *Research Chemist,*
National Institutes of Health
N.I.A.M.D., Laboratory of Chemistry
Section on Medicinal Chemistry
Bethesda, Maryland

- Dr. Thomas P. Johnston** *Head, Pharmaceutical Chemistry Division*
Southern Research Institute
Birmingham, Alabama
- Dr. Eugene C. Jorgensen** *Professor of Chemistry and Pharmaceutical Chemistry*
School of Pharmacy
University of California
San Francisco, California
- Dr. Madeleine M. Joullie** *Associate Professor of Chemistry*
University of Pennsylvania
Philadelphia, Pennsylvania
- Dr. Carl Kaiser** *Senior Investigator*
Smith Kline and French Laboratories
Philadelphia, Pennsylvania
- Dr. Paul D. Klimstra** *Senior Research Chemist*
G. D. Searle and Company
Chicago, Illinois
- Dr. Calvin Murry Kunin** *Professor of Preventive Medicine and Internal Medicine*
University of Virginia School of Medicine
Charlottesville, Virginia
- Dr. Arthur Lewis** *Research Chemist*
Organic Chemical Research Section
Lederle Laboratories, American Cyanamid Co.
Pearl River, New York
- Dr. A. J. Manson** *Assistant to the Director*
Ayerst Research Laboratories
Montreal, Canada
- Dr. Alfred N. Martin** *Dean and Professor of Physical Medicinal Chemistry*
Temple University, School of Pharmacy
Philadelphia, Pennsylvania
- Dr. Henry George Mautner** *Professor of Pharmacology*
Yale University School of Medicine
New Haven, Connecticut
- Dr. Everett Lee May** *Chief, Section on Medicinal Chemistry*
Laboratory of Chemistry
National Institutes of Health
Bethesda, Maryland
- Dr. Robert E. McMahon** *Research Advisor*
Lilly Research Laboratories
Indianapolis, Indiana
- Dr. John A. Montgomery** *Director, Organic Chemistry Research*
Southern Research Institute
Birmingham, Alabama
- Dr. Thomas S. Osdene** *Director of Research*
Philip Morris Research Center
Richmond, Virginia
- Genet L. Parks** *Research Instructor*
Department of Medicinal Chemistry
College of Pharmacy
University of Tennessee
Memphis, Tennessee
- Dr. Appasaheb Raojibhai Patel** *Scientist, Life Sciences Division*
Melpar, Inc.
Falls Church, Virginia
- Dr. D. Perlman** *Professor and Dean*
School of Pharmacy
University of Wisconsin
Madison, Wisconsin
- Dr. Roger Martin Pinder** *Chemical Defence Experimental Establishment*
Porton Down, Salisbury, Wiltshire, England
- Dr. Peter I. Pollak** *Director of Process Research*
Merck Sharp and Dohme Research Laboratories
Merck and Co., Inc.
Rahway, New Jersey
- Dr. William P. Purcell** *Professor of Medicinal Chemistry*
College of Pharmacy
University of Tennessee
Memphis, Tennessee
- Dr. Leonard Marcus Rice** *Professor and Head, Department of Pharmaceutical Chemistry*
Howard University College of Pharmacy
Washington, D.C.
- Dr. Oscar R. Rodig** *Associate Professor of Chemistry*
University of Virginia
Charlottesville, Virginia
- Dr. Daniel P. Roman** *Research Group Leader*
Organic Chemicals Division
Monsanto Company
St. Louis, Missouri
- Dr. Lewis J. Sargent** *Assistant Chief, Laboratory of Chemistry*
National Institute of Arthritis and Metabolic Diseases
National Institutes of Health
Bethesda, Maryland
- Dr. B. V. Rama Sastry** *Associate Professor of Pharmacology*
Vanderbilt University School of Medicine
Nashville, Tennessee

Dr. S. N. Sawhney *Reader, Department of Chemistry*
Kurukshetra University
Kurukshetra, India

Dr. Ignatius Schumacher *Senior Research Chemist*
Organic Chemicals Division
Monsanto Company
St. Louis, Missouri

Dr. Y. Fulmer Shealy *Head of the Medicinal Chemistry Division*
Southern Research Institute
Birmingham, Alabama

Dr. Robert G. Shepherd *Group Leader, Chemotherapy Department*
Lederle Laboratories, American Cyanamid Co.
Pearl River, New York

Judith Anne Singer *Research Associate, Chemistry Department*
Southwestern-at-Memphis
Memphis, Tennessee

Dr. R. John Stedman *Associate Professor of Physical-Organic Chemistry*
Temple University School of Pharmacy
Philadelphia, Pennsylvania

Dr. Clement A. Stone *Executive Director*
Merck Institute for Therapeutic Research
West Point, Pennsylvania

Dr. K. Sundaram *Research Instructor*
Department of Medicinal Chemistry
College of Pharmacy
University of Tennessee
Memphis, Tennessee

Dr. Bertil H. Takman *Astra Pharmaceutical Products, Inc.*
Worcester, Massachusetts

Dr. Andrew S. Tomcufcik *Group Leader*
Lederle Laboratories, American Cyanamid Co.
Pearl River, New York

Dr. John G. Topliss *Assistant Director of Chemical Research*
Schering Corporation
Bloomfield, New Jersey

Dr. David J. Trigg *Professor*
Department of Biochemical Pharmacology
School of Pharmacy and The Center for Theoretical Biology
State University of New York at Buffalo
Buffalo, New York

Dr. Eugene D. Weinberg *Professor of Microbiology*
Indiana University
Bloomington, Indiana

Dr. Thomas C. Westfall *Assistant Professor of Pharmacology*
University of Virginia School of Medicine
Charlottesville, Virginia

Dr. Donald Theodore Witiak *Associate Professor*
Division of Medicinal Chemistry
College of Pharmacy
Ohio State University
Columbus, Ohio

Dr. William L. Yost *Director of Chemical Development and Applied Mathematics*
CIBA Pharmaceutical Company
Division of CIBA Corporation
Summit, New Jersey

Dr. Charles Leon Zirkle *Associate Director, Chemistry*
Smith Kline and French Laboratories
Philadelphia, Pennsylvania

Preface to Part II

The sheer size of the task of covering the most important aspects of medicinal chemistry in one comprehensive survey made it advisable to separate this treatise into two parts. The first volume has dealt with the general theories of the whole field, and has presented drugs used in combating infections and parasitic diseases. Also included were drugs applicable to neoplastic and immunochemical disorders.

Part II contains chapters on biocatalysts and their structural variations, and then mainly covers drugs used in the treatment of many different types of functional disorders, whatever their etiology. Every effort has been made to survey all major events until the early part of 1968, and wherever possible, to the middle of

that year. Not only the highlights of the literature, but also those of medicinal thought and intuition up to 1968 will be found in these pages.

A book of the size of these two volumes places both the contributors and the editor under unusual pressure. They have to meet deadlines for the submission of manuscripts and proofs to the publisher on a tight schedule, and even the most determined efforts to avoid occasional mistakes may fail to eliminate all factual and typographical errors. We will be grateful to the readers of this treatise for calling any such errors to our attention.

ALFRED BURGER

Charlottesville, Virginia
December 1969

Contents Part II

30. The Vitamins. By <i>H. W. Dougherty and P. I. Pollak</i>	
I. Introduction	798
II. Thiamine	798
III. Riboflavin	800
IV. Niacin (Nicotinic Acid)	803
V. Vitamin C (Ascorbic Acid)	806
VI. Pantothenic Acid	808
VII. Vitamin E (Tocopherols)	809
VIII. Biotin	811
IX. Folic Acid	813
X. Vitamin A	814
XI. Vitamin D	820
XII. Lipoic Acid	822
XIII. Pyridoxine (Vitamin B ₆)	823
XIV. Vitamin B ₁₂	826
XV. Vitamin K and Some Dietary Factors	828
31. Thyroid Hormones and Antithyroid Drugs. By <i>Eugene C. Jorgensen</i>	
I. Introduction	838
II. Formation and Distribution of the Thyroid Hormones	838
III. Characterization and Synthesis of the Thyroid Hormones, Related Iodothyronines, and Analogs	843
IV. Structural Requirements for Thyroid Hormonal Activity	845
V. Theories of Mechanisms of Thyroid Hormonal Activity	850
VI. Antithyroid Drugs	852
32. Polypeptide and Protein Hormones. By <i>G. W. Anderson</i>	
I. Introduction	859
II. Pancreatic Hormones	860
III. Pituitary Hormones	860
IV. Neurohypophyseal Releasing Factors	863
V. Parathyroid Hormone and Calcitonin	863
VI. Intestinal Hormones	863
VII. Kinins	864
VIII. Peptide Drugs	865
33. Oxytocics. By <i>S. N. Sawhney</i>	
I. Introduction	868
II. Compounds of Natural Origin	868
III. Synthetic Compounds	872
34. Steroids. I. The Adrenal Cortex Hormones. By <i>Oscar R. Rodig</i>	
I. Introduction	878
II. Steroid Nomenclature	878
III. Isolation and Structure	880
IV. Production Site and Occurrence	881
V. Functions and Bioassays	888
VI. Diseases and Pathological Conditions Arising from Adrenal Function and Malfunction	889
VII. Approaches to Synthetic Cortisone	890
VIII. Structure-Activity Relationships	891
IX. Sites and Modes of Action	893
X. Major Clinical Applications	893
35. Steroids. II. Estrogens and Progestational and Contraceptive Agents. By <i>R. Deghenghi and A. J. Manson</i>	
I. Introduction	900
II. The Estrogens	900
III. Progestational Agents	911
IV. Steroid Oral Contraceptives	915
36. Steroids. III. Androgens and Anabolic Agents. By <i>R. E. Counsell and P. D. Klimstra</i>	
I. Introduction	923
II. Methods of Bioassay	925
III. Clinical Evaluation, Application, and Side Effects	926
IV. Mode of Action	926
V. Molecular Modifications	928
VI. Absorption, Distribution, and Metabolic Fate	935
VII. Hypotheses Concerning Structure and Activity	939
VIII. Current Research and Future Potential	942
37. Nonsteroidal Antiinflammatory Agents and Antipyretics. By <i>William E. Coyne</i>	
I. Introduction	953
II. Etiology of Inflammatory Diseases	953
III. The Inflammatory Response	953
IV. Biochemical Properties	954
V. Pharmacological Testing Methods	956

VI. Antiinflammatory Drugs	958	V. Drug Regulation of Lipid and Lipoprotein Metabolism.....	1134
VII. Current Trends	968	VI. Steroidal Antilipemic Agents	1136
VIII. Antipyretics	968	VII. Nonsteroidal Antilipemic Agents	1145
38. Diuretics. By John G. Topliss		VIII. Bile Acid Binding Substances	1164
I. Physiological, Pharmacological, and Clinical Considerations	976	43. Hypoglycemic Agents.	
II. Organomercurials	979	By Frederick A. Grunwald	
III. Xanthines	982	I. Introduction	1172
IV. Pyrimidines	982	II. Sulfonyleureas	1175
V. Thiazines	983	III. Biguanides	1178
VI. Carbonic Anhydrase Inhibitors	984	IV. Miscellaneous Hypoglycemic Agents	1179
VII. Aromatic Sulfonamides	987	V. Future Trends in Research on Diabetes and Hypoglycemic Agents	1181
VIII. Thiazides and Hydrothiazides	992	44. Plasma Expanders. By Sharon S. Hillery	
IX. Aldosterone Antagonists and Inhibitors	1001	I. Introduction	1185
X. Pteridines	1004	II. Salt Solutions	1185
XI. Acylphenoxycetic Acids	1007	III. Definition and Criteria	1185
XII. Pyrazines	1009	IV. Polysaccharides	1186
XIII. Miscellaneous	1011	V. Polyvinylpyrrolidone	1188
XIV. Conclusion	1012	VI. Other Plasma Expanders	1188
39. Antihypertensive Agents.		45. Neuropharmacology. By Eugene D. Brand and Thomas C. Westfall	
By William T. Comer and Allen W. Gomoll		I. Introduction	1190
I. Introduction	1019	II. The Nervous System: Development, Anatomy, and Physiology	1190
II. Mechanisms of Lowering Blood Pressure: Sites of Action	1021	III. Methods of Study of the Nervous System	1200
III. Techniques for Evaluation of Antihypertensive Activity	1024	IV. Junctional Transmission in the Peripheral Nervous System: Chemical Mechanism and Drug Action	1202
IV. Agents Acting on Central or Reflex Mechanisms	1026	V. Junctional Transmission in the Central Nervous System: Chemical Mechanisms and Drug Action	1222
V. Ganglionic Blocking Agents	1031	VI. Axonal Conduction: Chemical Mechanisms and Drug Action	1228
VI. Reserpine and Indole Derivatives	1033	46. Adrenergic Hormones and Drugs.	
VII. Postganglionic Sympathetic Blocking Agents	1039	By D. J. Trigg	
VIII. Adrenergic Receptor-Blocking Agents	1048	I. The Discovery, Localization, and Distribution of the Adrenergic Transmitter	1235
IX. Agents Acting Directly on Vascular Smooth Muscle	1056	II. Distribution of Norepinephrine, Epinephrine, and other Catecholamines	1235
40. Cardiac Drugs. By Charles S. Davis and Robert P. Halliday		III. Sympathomimetic Amines.....	1238
I. The Cardiac Glycosides.....	1065	IV. Pharmacological Actions of Sympathomimetic Amines.....	1238
II. Antianginal Drugs	1078	V. Structure-Activity Relationships of Sympathomimetic Amines.....	1244
41. Coagulants and Anticoagulants.		VI. The Metabolic Actions of Catecholamines	1269
By Stephen Divald and Madeleine M. Joullie		VII. The Structure and Function of Adrenergic Receptors.....	1273
I. Mechanism of Blood Clotting	1092		
II. Coagulants	1093		
III. Anticoagulants.....	1101		
42. Antilipemic Agents. By F. L. Bach			
I. Introduction	1123		
II. Serum Lipids and Lipoproteins.....	1124		
III. Classification of Hyperlipemic Conditions	1126		
IV. Metabolism of Cholesterol.....	1128		

VIII. Effects of Sympathomimetic Amines on the Central Nervous System	1281	IV. Gross Effects of Anticonvulsants ...	1389
IX. 5-Hydroxytryptamine.....	1282	V. Mechanisms of Anticonvulsant Action	1389
47. Cholinergics and Anticholinesterases.		VI. Absorption and Metabolism	1390
By <i>James E. Gearien</i>		VII. Structure-Activity Relationships ...	1396
I. Introduction	1296	VIII. Summary	1398
II. Acetylcholine and Analogs	1297	53. Analeptics. By <i>Leonard M. Rice and Edward C. Dobbs</i>	
III. Cholinergics Not Directly Analogous to Acetylcholine	1300	I. Introduction	1402
IV. The Receptor Site and Structure-Activity Relationships for Cholinergic Drugs	1301	II. Carbon Dioxide	1402
V. Anticholinesterases.....	1307	III. Camphor and Hexeton	1402
48. General Anesthetics. By <i>A. R. Patel</i>		IV. Xanthines	1403
I. Introduction	1314	V. Barbiturates	1403
II. Electronarcosis	1315	VI. Strychnine	1403
III. Theories of General Anesthesia ...	1315	VII. Picrotoxin.....	1404
IV. Medicinal Aspects of General Anesthetics	1318	VIII. Tetrazoles.....	1404
V. Metabolism of Volatile Anesthetics	1323	IX. Nalorphine and Levallorphan	1404
VI. Adjuncts to General Anesthesia ...	1324	X. Lobeline	1405
49. Analgetics. By <i>Arthur E. Jacobson, Everette L. May, and Lewis J. Sargent</i>		XI. Amphetamines and Methylphenidate	1405
I. Introduction	1327	XII. Nikethamide and Ethamivan	1406
II. Evaluation of Analgetic Agents.....	1327	XIII. Bemegride.....	1406
III. Morphine and Congeners	1330	XIV. Doxapram.....	1406
IV. Totally Synthetic Analgetics	1336	XV. Amiphenazole	1407
V. Narcotic Antagonists as Analgetics	1344	XVI. Dimeflin	1407
VI. Structure-Activity Considerations.....	1345	XVII. Miscellaneous Compounds	1407
VII. Metabolism and Mode of Action ...	1346	54. Antipsychotic Agents.	
50. Antitussives. By <i>Paul W. Collins</i>		By <i>Charles L. Zirkle and Carl Kaiser</i>	
I. Introduction	1351	I. Introduction	1410
II. Centrally Acting Antitussives	1352	II. Classes of Antipsychotic Agents ...	1412
III. Peripherally Acting Antitussives ...	1359	III. Clinical Aspects	1414
IV. Demulcents	1360	IV. Biological Actions	1418
V. Expectorants	1360	V. Effect of Chemical Structure on Antipsychotic Activity	1426
VI. Mucolytic Agents	1361	VI. Structure, Physical Properties, and Neuroleptic Activity	1461
51. Hypnotics and Sedatives.		55. Antidepressant Drugs. By <i>Carl Kaiser and Charles L. Zirkle</i>	
By <i>Henry G. Mautner and Harry C. Clemson</i>		I. Introduction	1470
I. Introduction	1365	II. Clinical Aspects	1471
II. Early Hypnotics	1366	III. Biological Actions	1473
III. Barbiturates and Related Compounds	1367	IV. Effect of Chemical Structure on Antidepressant Activity.....	1475
IV. Nonbarbiturate Hypnotics and Sedatives	1374	56. Antianxiety Agents. By <i>Scott J. Childress</i>	
V. Conclusion	1382	I. Introduction	1498
52. Anticonvulsants. By <i>Jaime N. Delgado and Eugene I. Isaacson</i>		II. Meprobamate and Analogs	1500
I. Epilepsy	1386	III. Benzodiazepines	1503
II. The Etiology of Epilepsy	1387	57. Hallucinogenic Agents. By <i>Alfred Burger</i>	
III. The Pharmacological Evaluation of Anticonvulsants	1389	I. Introduction	1511
		II. Biochemical and Pharmacological Effects	1511
		III. History of Psychedelic Drugs	1512
		IV. Clinical Uses	1515
		V. Chemistry and Structure-Activity Relationships	1515

58. Muscle Relaxants. By <i>Edward L. Engelhardt and Clement A. Stone</i>		
I. Introduction	1528	
II. Historical Background	1528	
III. Pharmacology of Polysynaptic Depressants	1528	
IV. Structure-Activity Relationships in the Polysynaptic Depressants ...	1529	
V. Muscle Relaxants Other than Polysynaptic Depressants	1535	
59. Antiparkinsonism Drugs. By <i>Edward L. Engelhardt and Clement A. Stone</i>		
I. Introduction	1538	
II. Pharmacology of Antiparkinsonism Drugs	1538	
III. Antiparkinsonism Drugs in Clinical Use	1539	
IV. Experimental Antiparkinsonism Agents	1539	
V. Biochemical Approaches to Parkinsonism	1540	
60. Anticholinergics: Antispasmodic and Antiulcer Drugs. By <i>B. V. Rama Sastry</i>		
I. Introduction	1544	
II. Biocomparative Assay of Anticholinergics	1547	
III. Solanaceous Alkaloids	1548	
IV. Synthetic Anticholinergics	1553	
V. Structure-Activity Relationships ...	1561	
VI. Interaction of Anticholinergics at the Muscarinic Receptors	1571	
VII. Therapeutic Uses of Anticholinergic Agents	1572	
VIII. Molecular Basis for the Side Effects of Anticholinergics	1573	
IX. Profile of Anticholinergic Activities of Various Agents	1574	
61. Curare and Curareform Drugs. By <i>Oliver Carrier, Jr.</i>		
I. Introduction	1581	
II. Curare and Curare Alkaloids	1583	
III. Curareform Alkaloids and Derivatives	1584	
IV. Other Curareform Drugs	1588	
V. Conclusion	1594	
62. Ganglionic Stimulants and Blocking Agents. By <i>Leonard M. Rice and Edward C. Dobbs</i>		
I. Introduction	1600	
II. Quaternary Ammonium Salts	1601	
III. Tertiary and Secondary Amines ...	1604	
IV. Trimethaphan and Miscellaneous Compounds	1604	
63. Local Anesthetics. By <i>Bertil H. Takman and George Camougis</i>		
I. Introduction	1607	
II. Historical Developments	1607	
III. Test Methods	1618	
IV. Mode of Action	1619	
V. Relationship between Chemical Structure and Biological Activity ...	1621	
VI. General Pharmacology and Toxicology	1623	
VII. Metabolism and Distribution	1624	
VIII. Currently used compounds	1625	
IX. Clinical Applications	1625	
X. Future Developments	1626	
64. Histamine. By <i>Jack Peter Green</i>		
I. Chemistry	1633	
II. Occurrence of Histamine in Nature	1633	
III. Formation of Histamine	1634	
IV. Subcellular Distribution of Histamine	1634	
V. Catabolism of Histamine	1635	
VI. Pharmacological Effects of Histamine	1637	
VII. The Role of Histamine in Normal Physiology	1637	
VIII. The Role of Histamine in Disease	1638	
IX. Drugs and Histamine	1639	
X. Activity of Histamine Analogs	1640	
XI. Activity of "Inactivation Products" of Histamine	1640	
65. Antiallergenic Agents. By <i>Donald T. Witiak</i>		
I. Introduction	1643	
II. Biochemical Causation of Allergy and Anaphylaxis	1643	
III. History of Antihistaminics	1645	
IV. Metabolism of Antihistaminics	1655	
V. Mode of Action of Antihistaminics	1656	
VI. Clinical Applications of Antihistaminics	1658	
VII. Structure Activity Relationships of Antihistaminics	1659	
VIII. Histidine Decarboxylase and Inhibitors	1661	
IX. Directions for Future Research ...	1661	
66. Radioprotective Drugs. By <i>William O. Foye</i>		
I. Introduction	1669	
II. Testing of Protective Agents	1669	
III. Protective Compounds	1670	
IV. Radiosensitizing Agents	1678	
V. Radioprotective Agents and Radiosensitizers in the Radiotherapy of Tumors	1678	
VI. Suggested Mechanisms of Protective Action	1679	

67. Diagnostic Agents. By <i>James H. Ackerman</i>		
I. Introduction	1686	
II. Radiopaques.....	1686	
III. Liver-Function Dyes	1697	
68. Cathartics and Other Gastrointestinal		
Drugs. By <i>Max Hubacher and</i>		
<i>Sidney Doernberg</i>		
I. Cathartics. Introduction.....	1700	
II. Anthraquinones and		
Anthraglycosides.....	1701	
III. Phthaleins	1704	
IV. Aromatics with one or more		
Hydroxyl Groups	1705	
V. Botanical Cathartics	1706	
VI. Miscellaneous Cathartics	1708	
VII. Constipating Agents	1708	
VIII. Gastric Antacids	1709	
IX. Astringents	1710	
X. Digestants.....	1710	
Author Index		A 1
Subject Index		
Parts I and II.....		11

